Pharmacokinetics, bioavailability, plasma protein binding and disposition of nalidixic acid in Rainbow Trout (Oncorhynchus mykiss)

References

• Austin B., Johnson C., Alderman D. J. Evaluation of substituted quinolones for the control of vibriosis in turbot (Scophthalmus maximus). Aquaculture 1982; 29: 227–239
   Google Scholar
• Barbeau G., Belanger P. Pharmacokinetics of nalidixic acid in old and young volunteers. Journal of Clinical Pharmacology 1982; 22: 490–492
   PubMed Web of Science ®Google Scholar
• Beyenbach K. W., Kirschner L. B. Kidney and urinary bladder function of the rainbow trout in Mg++ and Na+ excretion. American Journal of Physiology 1975; 229: 389–395
   PubMedGoogle Scholar
• BjÖRklund H. V., Bylund G. Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). Xenobiotica 1991; 21: 1511–1520
   PubMed Web of Science ®Google Scholar
• Bowser P. R., House M. In vitro sensitivity of some fish pathogens to the quinolones. Nalidixic acid, oxolinic acid and the fluoroquinolone enrofloxacin. Bulletin of the European Association of Fish Pathologists 1990; 10: 48–50
   Google Scholar
• Bowser P. R., Babish J. G. Enrofloxacin in salmonids. Veterinary and Human Toxicology 1991; 33: 46–48, (Suppl. 1)
   PubMedGoogle Scholar
• Droy B. F., Goodrich M. S., Lech J. J., Kleinow K. M. Bioavailability, disposition and pharmacokinetics of 14C-ormetoprim in rainbow trout (Salmo gairdneri). Xenobiotica 1990; 20: 147–157
   PubMed Web of Science ®Google Scholar
• Endo T., Sakuma M., Tanaka H., Ogishima K., Hara T., Ohsima S., Sato Y. Application of oxolinic acid as a chemotherapeutic agent against infectious diseases in fish II. Explanation of chemotherapeutic effects by whole body autobacteriography. Bulletin of the Japanese Society of Scientific Fisheries 1973; 39: 173–177
   Google Scholar
• Fabacher D. L. Hepatic microsomes from freshwater fish, II. Reduction of benzo(a)pyrene by the fish, anesthetics quinaldine sulfate and tricaine. Comparative Biochemistry and Physiology 1982; 73: 285–288
   Google Scholar
• Gibaldi M., Perrier D. Drugs and the Pharmaceutical Sciences Vol. 15 of Pharmacokinetics. Marcel Dekker, New York 1982
   Google Scholar
• Gingerich W. H., Drottar K. R. Plasma catecholamine in rainbow trout (Salmo gairdneri) at rest and after anesthesia and surgery. General and Comparative Endocrinology 1989; 73: 390–397
   PubMed Web of Science ®Google Scholar
• Hunn J. B., Willford W. A. The effect of anesthetization and urinary bladder catheterization on renal function of rainbow trout. Comparative Biochemistry and Physiology 1970; 33: 805–812
   PubMedGoogle Scholar
• Izumi T., Kitagawa T. Protein binding of quinolonecarboxylic acids. I. Cinoxacin, nalidixic acid and pipemidic acid. Chemical and Pharmaceutical Bulletin 1989; 37: 742–745
   PubMed Web of Science ®Google Scholar
• Jarboe H. H., Kleinow K. M. Matrix Solid Phase Dispersion (MSPD) isolation and liquid chromatographic determination of oxolinic acid in channel catfish (Ictalurus punctatus) muscle tissue. Journal of the Association of Official Analytical Chemists 1992; 75: 428–432
   Google Scholar
• Kasuga Y., Sugitani A., Makoto A., Morikawa S. Residue levels of nalidixic acid and its metabolites in cultured rainbow trout. Journal of the Food Hygienic Society of Japan 1987; 28: 267–272
   Google Scholar
• Kleinow K. M. Experimental techniques for pharmacokinetic data collection in free-swimming fish. Aquatic Toxicology and Risk Assessment, M. A. Mayes, M. G. Barron. American Society for Testing and Materials, Philadephia 1991; Vol. 14: 131–138, ASTM STP 1124
   Google Scholar
• Kleinow K. M., Beilfuss W. L., Jarboe H. H., Droy B. F., Lech J. J. The pharmacokinetics, bioavailability, distribution, and metabolism of sulfadimethoxine in the rainbow trout (Oncorhynchus mykiss). Canadian Journal of Fisheries and Aquatic Science 1992a; 49: 1070–1077
   Web of Science ®Google Scholar
• Kleinow K. M., Haasch M. L., Lech J. J. The effect of tricaine anesthesia upon induction of select P-450 dependent monooxygenase activities in rainbow trout (Salmo gairdneri). Aquatic Toxicology 1986; 8: 231–241
   Web of Science ®Google Scholar
• Kleinow K. M., Jarboe H. H., Toth B. R., Shoemaker K. E., Greenlees K. J. Pharmacokinetics, bioavailability and disposition of oxolinic acid in channel catfish (Ictalurus punctatus) and rainbow trout (Oncorhynchus mykiss): influence of species and temperature. Canadian Journal of Fisheries and Aquatic Sciences 1992b, submitted
   Google Scholar
• Kleinow K. M., Mc Elroy A. E. Comparative plasma protein binding of ormetoprim in marine and freshwater species. Bulletin of the Mount Desert Island Biological Laboratory 1990; 29: 135–136
   Google Scholar
• Mannisto P. T. Pharmacokinetics of nalidixic acid and oxolinic acid in healthy women. Clinical Pharmacology Therapeutics 1976; 19: 37–46
   PubMed Web of Science ®Google Scholar
• Nakamura K., Asano R., Hokari S. Pharmacokinetics of nalidixic acid in the dog. Bulletin of the College of Agriculture and Veterinary Medicine, Nihon University 1985; 42: 27–30
   Google Scholar
• Portmann G. A., Mcchesney E. W., Stander H., Moore W. E. Pharmacokinetic model for nalidixic acid in man. II. Parameters for absorption, metabolism, and elimination. Journal of the Pharmaceutical Sciences 1966; 55: 72–78
   PubMed Web of Science ®Google Scholar
• Sokal R. R., Rolf J. F. Introduction to Biostatistics. W.-H. Freeman, San Francisco, CA 1973
   Google Scholar
• Vree T. B., Winjnands W. J. A., Baars A. M., Hekster Y. A. Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation. Pharmaceutish Weekblad 1988; 10: 193–199, Scientific Edition
   Google Scholar
• Wagner J. G. Nonlinear pharmacokinetics. I. Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publ., Hamilton, IL 1979; 247–248
   Google Scholar
• Wright H. T., Nurse K. C., Goldstein S. D. Nalidixic acid, oxolinic acid and novobiocin inhibit yeast glycyl-and leucyl-transfer RNA synthetase. Science 1981; 213: 455–456
   PubMedGoogle Scholar